TY - JOUR T1 - COVID-19 in regions with low prevalence and low density of population. An uncertainty dynamic modeling approach JF - medRxiv DO - 10.1101/2020.10.21.20215418 SP - 2020.10.21.20215418 AU - José M. Garrido AU - David Martínez-Rodríguez AU - Fernando Rodríguez-Serrano AU - Javier Díez-Domingo AU - COVID-19_Granada Study Group AU - Rafael-J. Villanueva Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/25/2020.10.21.20215418.abstract N2 - The coronavirus disease 2019 (COVID-19) that emerged in China at the end of 2019 has spread worldwide. In this article, we present a mathematical SEIR model focused on analysing the transmission dynamics of COVID-19, the patients circulating in the hospitals and evaluating the effects of health policies and vaccination on the control of the pandemic. We tested the model using registered cases and population data from the province of Granada (Spain), that represents a population size near 1 million citizens with low density of population and low prevalence. After calibrating the model with the data obtained from 15 March to 22 September 2020, we simulate different vaccination scenarios - including effectiveness and availability date - in order to study the possible evolution of the disease. The results show that: 1) infected will increase until 5.6% - 7.4% of the total population over next 3-4 months (2nd wave); 2) vaccination seems not to be enough to face the pandemic and other strategies should be used; 3) we also support the claim of the WHO about the effectiveness of the vaccine, that should be, at least, of 50% to represent a substantial progress against the COVID-19; 4) after the 2nd wave, the return to normal life should be controlled and gradual to avoid a 3rd wave. The proposed study may be a useful tool for giving insight into the transmission dynamics of SARS-CoV-2 and to design vaccination and health policies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSpanish Ministerio de Economia, Industria y Competitividad (MINECO), the Agencia Estatal de Investigacion (AEI) and Fondo Europeo de Desarrollo Regional (FEDER UE) grant MTM2017-89664-P; European Union through the Operational Program of the [European Regional Development Fund (ERDF) / European Social Fund (ESF)] of the Valencian Community 2014-2020. Files: GJIDI/2018/A/010 and GJIDI/2018/A/009; Ramon Areces Foundation, Madrid, Spain (CIVP18A3920).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The CEI (Investigation Ethical Committee) of the province of Granada has approved the research. The electronically signed document with the ethical agreement is attached as Supplementary File with the name "peiba_COVID-19.pdf". According to this document, all the requirements needed are followed according with the ethical principles of this type of studies. The capacity of the investigators and the resources are appropriated. All the risks and concerns of the patients are justified. The economic aspects involved do not interfere with ethic postulates. The committee consideres that this study can be done in the centres of Andalusia.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the study is provided in the manuscript. ER -